Your browser doesn't support javascript.
loading
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
Langerak, Anton W; Ritgen, Matthias; Goede, Valentin; Robrecht, Sandra; Bahlo, Jasmin; Fischer, Kirsten; Steurer, Michael; Trnený, Marek; Mulligan, Stephen P; Mey, Ulrich J M; Trunzer, Kerstin; Fingerle-Rowson, Günter; Humphrey, Kathryn; Stilgenbauer, Stephan; Böttcher, Sebastian; Brüggemann, Monika; Hallek, Michael; Kneba, Michael; van Dongen, Jacques J M.
Affiliation
  • Langerak AW; Department of Immunology, Laboratory for Medical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Ritgen M; Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.
  • Goede V; Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany.
  • Robrecht S; German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
  • Bahlo J; German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
  • Fischer K; German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
  • Steurer M; German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
  • Trnený M; Division of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria.
  • Mulligan SP; Charles University Hospital, Prague, Czech Republic.
  • Mey UJM; Royal North Shore Hospital, University of Sydney, Sydney, Australia.
  • Trunzer K; Kantonsspital Graubünden, Chur, Switzerland.
  • Fingerle-Rowson G; Pharma Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Humphrey K; Pharma Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Stilgenbauer S; Pharma Development Oncology, Roche Products Ltd, Welwyn, United Kingdom.
  • Böttcher S; Internal Medicine III, University of Ulm, Ulm, Germany.
  • Brüggemann M; Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.
  • Hallek M; Clinic III, Hematology, Oncology and Palliative Medicine, University of Rostock, Rostock, Germany.
  • Kneba M; Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.
  • van Dongen JJM; German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany.
Blood ; 133(5): 494-497, 2019 01 31.
Article in En | MEDLINE | ID: mdl-30455380
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Chlorambucil / Neoplasm, Residual / Antibodies, Monoclonal, Humanized / Rituximab / Antineoplastic Agents Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Humans / Middle aged Language: En Journal: Blood Year: 2019 Document type: Article Affiliation country: Netherlands Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Lymphocytic, Chronic, B-Cell / Antineoplastic Combined Chemotherapy Protocols / Chlorambucil / Neoplasm, Residual / Antibodies, Monoclonal, Humanized / Rituximab / Antineoplastic Agents Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Humans / Middle aged Language: En Journal: Blood Year: 2019 Document type: Article Affiliation country: Netherlands Country of publication: United States